One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
CAR T-cell therapy for solid tumours
doi : 10.1016/S1470-2045(21)00353-3
Volume 22, Issue 7, July 2021, Page 893
Chemoimmunotherapy in urothelial cancer: concurrent or sequential?
Zeynep BZenginaLuisMezaaSumanta KPalaPetrosGrivasb
doi : 10.1016/S1470-2045(21)00284-9
Volume 22, Issue 7, July 2021, Pages 894-896
Gauging the quality-of-life benefits of immunotherapy in hepatocellular carcinoma
NicolaPersoneniabLorenzaRimassaab
doi : 10.1016/S1470-2045(21)00258-8
Volume 22, Issue 7, July 2021, Pages 896-898
Colorectal cancer screening in Europe: what are the next steps?
IsmailGogenuraCamillaQvortrupb
doi : 10.1016/S1470-2045(21)00276-X
Volume 22, Issue 7, July 2021, Pages 898-899
A step closer to a personalised approach for Lynch syndrome
VeroushkaBallestera
doi : 10.1016/S1470-2045(21)00295-3
Volume 22, Issue 7, July 2021, Pages 899-901
Spinal stereotactic radiotherapy for painful spinal metastasis
Joanne Mvan der VeldenaYvette Mvan der Lindenb
doi : 10.1016/S1470-2045(21)00268-0
Volume 22, Issue 7, July 2021, Pages 901-903
Immunotherapy in ovarian cancer: we are not there yet
EmmaBarberabDanielaMateiabc
doi : 10.1016/S1470-2045(21)00303-X
Volume 22, Issue 7, July 2021, Pages 903-905
Endocrinopathies induced by immune checkpoint inhibitors: the need for clear endocrine diagnosis
RuthPercikaJamesLarkinbDaniel LMorgansteinbc
doi : 10.1016/S1470-2045(21)00305-3
Volume 22, Issue 7, July 2021, Pages 905-907
Biomedicine and the soul of medicine: optimising the balance
GaryRodinaChristianNtizimirabRichardSullivanc
doi : 10.1016/S1470-2045(21)00271-0
Volume 22, Issue 7, July 2021, Pages 907-909
Real-time fluorescence imaging for cancer surgery: a pathologist's perspective
Sachin CSarodeaGargi SSarodea
doi : 10.1016/S1470-2045(21)00239-4
Volume 22, Issue 7, July 2021, Page e282
Real-time fluorescence imaging for cancer surgery: a pathologist's perspective – Authors' reply
Lorraine JLauwerendsacPieter B A Avan DrieldSenadaKoljenovi?bcAlexander LVahrmeijereStijnKeereweerac
doi : 10.1016/S1470-2045(21)00335-1
Volume 22, Issue 7, July 2021, Page e283
Second-line FOLFOX chemotherapy for advanced biliary tract cancer
FangqiangWei
doi : 10.1016/S1470-2045(21)00211-4
Volume 22, Issue 7, July 2021, Page e284
Second-line FOLFOX chemotherapy for advanced biliary tract cancer
GiovanniBrandiabGiorgioFregaabAlessandroRizzoab
doi : 10.1016/S1470-2045(21)00243-6
Volume 22, Issue 7, July 2021, Page e285
Second-line FOLFOX chemotherapy for advanced biliary tract cancer
TiffanyFooaGanessanKichenadasseabcAmiteshRoyabChristos SKarapetisab
doi : 10.1016/S1470-2045(21)00269-2
Volume 22, Issue 7, July 2021, Page e286
Second-line FOLFOX chemotherapy for advanced biliary tract cancer
RajaPramanikaAtulSharmaaAkashKumara
doi : 10.1016/S1470-2045(21)00280-1
Volume 22, Issue 7, July 2021, Page e287
Second-line FOLFOX chemotherapy for advanced biliary tract cancer – Authors' reply
AngelaLamarcaaDaniel HPalmereHarpreet SinghWasanfPaul JRossgYuk TingMahArvindAroraiStephenFalkjRoopinderGillmorekJonathanWadsleylKinnariPatelmAlanAnthoneynAnthonyMaraveyasoTimIvesonpJustin SWatersqClaireHobbsrSafiaBarbercW DavidRydercJohnRamagesLinda MDaviesbJohn ABridgewatertJuan WValleadon behalf of theAdvanced Biliary Cancer Working Group
doi : 10.1016/S1470-2045(21)00341-7
Volume 22, Issue 7, July 2021, Pages e288-e289
Patient selection for immunotherapy in head and neck cancer
PierluigiBonomoaEsterOrlandibPaoloBossic
doi : 10.1016/S1470-2045(21)00237-0
Volume 22, Issue 7, July 2021, Page e290
Patient selection for immunotherapy in head and neck cancer – Authors' reply
Nancy YLeeaRobert LFerrisbStevenDe BeukelaercEzraCohend
doi : 10.1016/S1470-2045(21)00339-9
Volume 22, Issue 7, July 2021, Pages e291-e292
Partial breast irradiation with intraoperative radiotherapy in the ELIOT trial
GerdFastneraRolandReitsamerbFelixSedlmayera
doi : 10.1016/S1470-2045(21)00257-6
Volume 22, Issue 7, July 2021, Page e293
Partial breast irradiation with intraoperative radiotherapy in the ELIOT trial
OritKaidar-Personab†PhilipPoortmanscd†
doi : 10.1016/S1470-2045(21)00259-X
Volume 22, Issue 7, July 2021, Page e294
Partial breast irradiation with intraoperative radiotherapy in the ELIOT trial
Jayant SVaidyaaMaxBulsarabSamueleMassarutcElenaSperkdFrederikWenzeJeffrey STobiasfTARGIT-A trial authors
doi : 10.1016/S1470-2045(21)00278-3
Volume 22, Issue 7, July 2021, Pages e295-e296
Partial breast irradiation with intraoperative radiotherapy in the ELIOT trial
Gustavo NaderMartaa†IcroMeattinib†
doi : 10.1016/S1470-2045(21)00260-6
Volume 22, Issue 7, July 2021, Page e297
Partial breast irradiation with intraoperative radiotherapy in the ELIOT trial – Authors' reply
RobertoOrecchiaa†PatrickMaisonneuvebMaria CristinaLeonardic†
doi : 10.1016/S1470-2045(21)00355-7
Volume 22, Issue 7, July 2021, Page e298
Adjuvant therapy in stage IIIA melanoma
ElifHindiéa
doi : 10.1016/S1470-2045(21)00346-6
Volume 22, Issue 7, July 2021, Page e299
Adjuvant therapy in stage IIIA melanoma - Authors' reply
Alexander M MEggermontaStefanSuciubCarolineRobertc
doi : 10.1016/S1470-2045(21)00354-5
Volume 22, Issue 7, July 2021, Page e300
Intensifying neoadjuvant treatment in locally advanced rectal cancer
SwapnilPatelaAkhilKapoorb
doi : 10.1016/S1470-2045(21)00304-1
Volume 22, Issue 7, July 2021, Page e301
Intensifying neoadjuvant treatment in locally advanced rectal cancer – Authors' reply
ThierryConroyabFlorenceCastancSophieGourgoucFrédéricMarchalaChristopheBorgd
doi : 10.1016/S1470-2045(21)00340-5
Volume 22, Issue 7, July 2021, Page e302
UK Government urged to recognise post-COVID-19 cancer backlog
EmmaWilkinson
doi : 10.1016/S1470-2045(21)00330-2
Volume 22, Issue 7, July 2021, Page 910
Calls to scale up international funding for tobacco control
Talha KhanBurki
doi : 10.1016/S1470-2045(21)00331-4
Volume 22, Issue 7, July 2021, Page 911
2021 ASCO Virtual Annual Meeting
M?rciaCosta
doi : 10.1016/S1470-2045(21)00338-7
Volume 22, Issue 7, July 2021, Pages 912-913
Greater price transparency needed for thyroid cancer treatment among US cancer centres
Mary BethNierengarten
doi : 10.1016/S1470-2045(21)00345-4
Volume 22, Issue 7, July 2021, Page 914
The Dietary Supplement Health And Education Act: are we healthier and better informed after 27 years?
Tristan MSissungaLisa MCordesaWilliam DFigga
doi : 10.1016/S1470-2045(21)00084-X
Volume 22, Issue 7, July 2021, Pages 915-916
Is complete mesocolic excision superior to conventional colectomy for colon cancer?
DaniloMiskovicRezaMirnezami
doi : 10.1016/S1470-2045(21)00256-4
Volume 22, Issue 7, July 2021, Pages 917-918
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
ProfArjun VBalarMDaProfAshish MKamatMDbGirish SKulkarniMDcProfEdward MUchioMDdJoost LBoormansMDeMathieuRoumiguiéMDfLaurence E MKriegerMDgEric ASingerMDhProfDean FBajorinMDiPetrosGrivasMDjHo KyungSeoMDkProfHiroyukiNishiyamaMDlProfBadrinath RKonetyMDmHaojieLiPhDnKijoengNamPhDnEktaKapadiaMDnTaraFrenklMDnProfRonaldde WitMDe
doi : 10.1016/S1470-2045(21)00147-9
Volume 22, Issue 7, July 2021, Pages 919-930
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
panelThomasPowlesMDabTiborCs?sziMDcMustafa?zgüro?luMDdNobuakiMatsubaraMDeLajosGécziMDfSusanna Y-SChengMDgProfYvesFradetMDhProfStephaneOudardMDiChristofVulstekeMDjkRafaelMorales BarreraMDlAudeFléchonMDmSeydaGunduzMDnoYohannLoriotMDpAlejoRodriguez-VidaMDqRonacMamtaniMDrEvan YYuMDstKijoengNamPhDuKentaroImaiMDuBlancaHomet MorenoMDuAjjaiAlvaMDv
doi : 10.1016/S1470-2045(21)00152-2
Volume 22, Issue 7, July 2021, Pages 931-945
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study
Chung-HanLeeMDaAmishi YogeshShahMDbDrewRascoMDcArpitRaoMDdMatthew HTaylorMDeChristopherDi SimoneMDfJames JHsiehMDgAlvaroPintoMDhDavid RShafferMDiReginaGirones SarrioMDjAllen LeeCohnMDkProfNicholas JVogelzangMDlMehmet AsimBilenMDmSaraGunnestad RibeMDnMusaberkGokselMDo?yvind KrohnTenn?eMDpDonaldRichardsMDqRandy FSweisMDrJayCourtrightMDsDanielHeinrichMDtSharadJainMDuJaneWuPhDvEmmett VSchmidtMDxRodolfo FPeriniMDxPeterKubiakMDwChinyere EOkparaPhDyAlan DSmithMDyRobert JMotzerMDa
doi : 10.1016/S1470-2045(21)00241-2
Volume 22, Issue 7, July 2021, Pages 946-958
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study
Justin FGainorMDaProfGiuseppeCuriglianoMDbProfDong-WanKimMDcProfDae HoLeeMDdProfBenjaminBesseMDefChristina SBaikMDgRobert CDoebeleMDhPhilippe ACassierMDiGilbertoLopesMDjDaniel S WTanMDkElenaGarraldaMDlProfLuis GPaz-AresMDmProfByoung ChulChoMDnShirish MGadgeelMDoProfMichaelThomasMDpStephen VLiuMDqMatthew HTaylorMDrAaron SMansfieldMDsViola WZhuMDtCorinneCliffordMSuHuiZhangPhDvMichaelPalmerPhDwJenniferGreenBSxChristopher DTurnerMDxVivekSubbiahMDy
doi : 10.1016/S1470-2045(21)00247-3
Volume 22, Issue 7, July 2021, Pages 959-969
Impact of COVID-19 on cancer care in India: a cohort study
ProfPriyaRanganathanMDaProfManjuSengarDMaProfGirishChinnaswamyMDaGauravAgrawalMSbRajkumarArumughamDMcRajivBhattMSdRameshBilimaggaMDeJayantaChakrabartiDNBfArunChandrasekharanDMgHarit KumarChaturvediMChhRajivChoudhrieMChiMitaliDandekarMSjAshokDasMSkVineetaGoelDNBlCalebHarrisMChmSujai KolnadguthuHegdeMSnProfNarendraHulikalMChoDeepaJosephMDpRajeshKanthariaMSqAzizullahKhanDNBrRohanKhardeMDsProfNavinKhattryDMaProfMaqbool MLoneMDtProfUmeshMahantshettyMDuProfHemantMalhotraMDvHariMenonDMwDeeptiMishraMChxProfRekha ANairMDyProfShashank JPandyaMChzNidhiPatniMDaaJeremyPautuDMabProfSimonPavamaniMDacProfSatyajitPradhanMDadSubramanyeshwar RaoThammineediMChaeProfGSelvaluxmyMDafProfKrishnaSharanMDagB KSharmaMSahJayeshSharmaMSaiProfSureshSinghMSajGowtham ChandraSrungavarapuMDSakRSubramaniamMDalProfRajendraTopraniMChamRamanan VenkatRamanMSanProfRajendra AchyutBadweMSaProfC SPrameshMSaon behalf of theNational Cancer Grid of India
doi : 10.1016/S1470-2045(21)00240-0
Volume 22, Issue 7, July 2021, Pages 970-976
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study
ProfZhenggangRenMDacProfJianmingXuMDdProfYuxianBaiMDfProfAibingXuMDgProfShundongCangMDhProfChengyouDuMDiProfQiuLiMDjProfYinyingLuMDeProfYajinChenMDkProfYabingGuoMDmProfZhendongChenMDnProfBaoruiLiuMDoProfWeidongJiaMDpProfJianWuMDqProfJunyeWangMDrProfGuoliangShaoMDsProfBixiangZhangMDtProfYunfengShanMDuProfZhiqiangMengMDvProfJianbingWuMDwProfShanzhiGuMDxProfWeiYangMDyProfChaoLiuMDlProfXuetaoShiMDzProfZhenyuanGaoMDaaProfTaoYinMDabProfJiuweiCuiMDacProfMingHuangMDadProfBaocaiXingMDaeProfYileiMaoMDafProfGaojunTengMDagProfYanruQinMDahProfJinhaiWangMDaiProfFengXiaMDajProfGuowenYinMDakYongYangMDalMingxiaChenMScamYanWangMDalHuiZhouMDalProfJiaFanMDbc†on behalf of theORIENT-32 study group†
doi : 10.1016/S1470-2045(21)00252-7
Volume 22, Issue 7, July 2021, Pages 977-990
Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial
ProfPeter RGalleMDaProfRichard SFinnMDbProfShukuiQinMDcMasafumiIkedaMDdProfAndrew XZhuMDefProfTae-YouKimMDgProfMasatoshiKudoMDhValeriyBrederMDiProfPhilippeMerleMDjProfAhmedKasebMDkDanengLiMDlSohailMullaPhDmWendyVerretPhDnDerek-ZhenXuMDpSairyHernandezPhDnBeiyingDingPhDoJuanLiuPhDqChenHuangMDrProfHo YeongLimMDsProfAnn-LiiChengMDtProfMichelDucreuxMDu
doi : 10.1016/S1470-2045(21)00151-0
Volume 22, Issue 7, July 2021, Pages 991-1001
Colorectal cancer incidence, mortality, and stage distribution in European countries in the colorectal cancer screening era: an international population-based study
RafaelCardosoMScabFengGuoPhDbcThomasHeisserMScbcMonikaHacklPhDePetraIhleBAeHarlindeDe SchutterPhDfNancyVan DammePhDfProfZdravkaValerianovaPhDgTrajanAtanasovPhDgOnd?ejM?jekPhDhiJanMu??kPhDhiProfMef ChristinaNilbertPhDjkAnne JulieTybjergMScjKaireInnosPhDlMargitM?giMDmNeaMalilaPhDnAnne-MarieBouvierPhDoVéroniqueBouvierMDpProfGuyLaunoyPhDqrAnne-SophieWoronoffMDsMélanieCariouMSctProfMichelRobaszkiewiczPhDtPatriciaDelafosseMDuFlorencePoncetMDuProfAlexanderKatalinicMDvPaul MWalshPhDwCarloSenoreMScxStefanoRossoMDyIevaVincer?evskien?PhDzProfValery E P PLemmensPhDaaabMarloes A GElferinkPhDaaTom B?rgeJohannesenPhDacProfHartwigK?rnerPhDadaeProfFrankPfefferPhDaeafMaria JoséBentoPhDagahaiJessicaRodriguesMScagahFilipaAlves da CostaPhDajAnaMirandaMScajProfVesnaZadnikPhDakTina?agarPhDakArantzaLopez de Munain MarquesBScalRafaelMarcos-GrageraPhDamanaoMontsePuigdemontBSNamanJaumeGalceranPhDapMariàCarullaMDapMar?a-DoloresChirlaquePhDaoapMonicaBallestaBScaoaqProfKristinaSundquistMDarasatProfJanSundquistMDarasatMarcoWeberauAndreaJordanauChristianHerrmannPhDavawMohsenMousaviMDavawAntonRyzhovPhDaxayMichaelHoffmeisterPhDcProfHermannBrennerMDacd
doi : 10.1016/S1470-2045(21)00199-6
Volume 22, Issue 7, July 2021, Pages 1002-1013
Variation in the risk of colorectal cancer in families with Lynch syndrome: a retrospective cohort study
The International Mismatch Repair Consortium†
doi : 10.1016/S1470-2045(21)00189-3
Volume 22, Issue 7, July 2021, Pages 1014-1022
Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2/3 trial
ProfArjunSahgalMDaSten DMyrehaugMDaShankarSivaMBBSeGiuseppina LMasucciMDfPejman JMaralaniMDbProfMichaelBrundageMDgJamesButlerMDiProfEdwardChowMBBSaProfMichael GFehlingsMDcMathewFooteMBBSjZsoltGabosMDkJeffreyGreenspoonMDlMarcKerbaMDmYoungLeePhDaMitchellLiuMDnStanley KLiuMDaIsabelleThibaultMDoProfRebecca KWongMDdMaaikeHumPhDhKeyueDingPhDhProfWendy RParulekarMDhon behalf of thetrial investigators†
doi : 10.1016/S1470-2045(21)00196-0
Volume 22, Issue 7, July 2021, Pages 1023-1033
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study
ProfEricPujade-LauraineMDaProfKeiichiFujiwaraMDbProfJonathan ALedermannMDcdProfAmit MOzaMDeRebeccaKristeleitMDcdProfIsabelle-LaureRay-CoquardMDfgProfGary ERichardsonMDhProfCristianaSessaMDiKanYonemoriMDjSusanaBanerjeeMDklAlexandraLearyMDgmProfAnna VTinkerMDnProfKyung HaeJungMDoRadoslawMadryMDpSang-YoonParkMDqCharles KAndersonMDrFabianZohrenMDsRoss AStewartPhDtCaimiaoWeiPhDuSamuel SDychterMDtProfBradley JMonkMDv
doi : 10.1016/S1470-2045(21)00216-3
Volume 22, Issue 7, July 2021, Pages 1034-1046
Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer
Maria AliceFranzoiMDaElisaAgostinettoMDabMartaPerachinoMDcdLuciaDel MastroMDdeEvandrode AzambujaMDaInesVaz-LuisMDfProfAnn HPartridgeMDgMatteoLambertiniMDcd
doi : 10.1016/S1470-2045(20)30666-5
Volume 22, Issue 7, July 2021, Pages e303-e313
The concept and use of the neoadjuvant rectal score as a composite endpoint in rectal cancer
RobertGlynne-JonesFRCRaStuartGlynne-JonesBMBSb
doi : 10.1016/S1470-2045(21)00053-X
Volume 22, Issue 7, July 2021, Pages e314-e326
Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG)
LauraBiganzoliMDaNicol? Matteo LucaBattistiMDbcProfHansWildiersPhDdAmeliaMcCartneyMBBSeGiuseppeCollocaPhDfProfIan HKunklerFRCRgProfMaria-Jo?oCardosoPhDhProfKwok-LeungCheungMDiNienke Aafkede GlasPhDjRubina MTrimboliMDkProfBeatrizKorc-GrodzickiPhDlEnriqueSoto-Perez-de-CelisMDmAntonioPontiMDnJaniceTsangMDoLorenzaMarottiPhDpKarenBennBAqMatti SAaproMDrEtienne G CBrainMDs
doi : 10.1016/S1470-2045(20)30741-5
Volume 22, Issue 7, July 2021, Pages e327-e340
Richter's transformation in the heart
AndreaMarraMDaFrancescoAdamoMScaStefanoBaldoniMScaMaria ElenaLaurentiMDbMicheleGiansantiMDbStefanoPasquinoMDcBarbaraBigernaMScaDanieleSorciniPhDaAriannaStellaMScaValerioGuarenteMDaRobertoLimongelloMDaVincenzoPerrielloMDaGiovanniMartinoMDaStefanoAscaniMDaProfBrunangeloFaliniMDaPaoloSportolettiMDa
doi : 10.1016/S1470-2045(21)00153-4
Volume 22, Issue 7, July 2021, Page e341
